Protalex, Inc. Files Patent on Its Innovative Therapy for Rheumatoid Arthritis

Apr 23, 2002, 01:00 ET from Protalex, Inc.

    ALBUQUERQUE, N.M., April 23 /PRNewswire-FirstCall/ --
 Protalex, Inc. (OTC Bulletin Board:   PRTX) recently filed a broad and
 far-reaching patent application covering its unique approach to the treatment
 of rheumatoid arthritis and other immune disorders.  Capping two years of
 animal studies and extensive research with in vitro systems, the patent
 addresses an entirely new concept of therapy for diseases notoriously
 difficult to treat.  The Protalex drug (PRTX-001) can actually regulate or
 normalize aberrant functions in cells affected by autoimmune disease. Unlike
 existing therapy, this permits the tissues to return to a healthy functional
 state, slowing or stopping the inflammatory process, and potentially reversing
 earlier damage to structures such as joint cartilage.  The patent covers the
 therapeutic use of PRTX-001 by oral administration or injection, in the
 treatment of all of the recognized immune disorders, including many of the
 most disabling human diseases such as lupus erythematosus, diabetes mellitus
 and asthma.
     The Protalex patent forms the basis for the filing of an Investigational
 New Drug (IND) application for PRTX-001 with the FDA.  Building on highly
 successful animal testing recently completed, the company expects to enter
 full clinical trials in a number of sites before the end of the year.  These
 human studies will concentrate on treatment of rheumatoid arthritis, a chronic
 and debilitating disease affecting more than 2 million people in the United
 States alone.  Protalex President John E. Doherty commented, "The Company's
 discovery, directed by Dr. Paul L. Mann, has led to an entirely new approach
 to the treatment of this devastating disorder.  Thousands of people whose
 affliction had been thought beyond the reach of medicine can now look forward
 not just to relief of symptoms, but perhaps to the reversal of their disease."
 After proof of PRTX-001's safety and efficacy in humans, Protalex will seek
 FDA approval for its introduction as a prescribed pharmaceutical agent.
     Statements in this press release that are not strictly historical are
 "forward looking" statements within the meaning of Section 27A of the
 Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
 These statements involve a high degree of risk and uncertainty, are
 predictions only and actual events or results may differ materially from those
 projected in such forward-looking statements.  Factors that could cause or
 contribute to differences include the Company's limited operating history,
 uncertainty regarding viability and market acceptance of the Company's
 products, and the Company's dependence on reimbursement by third parties.
 These factors and others are more fully described in the section entitled
 "Risks Related to the Company's Business" in the Company's Registration
 Statement on Form 10-SB (File No. 00028385) as filed with the Securities and
 Exchange Commission.
                     MAKE YOUR OPINION COUNT -  Click Here

SOURCE Protalex, Inc.